REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Eligibility Criteria

• 1. Age 18 years or older
• 2. Histologic diagnosis of non-small cell lung cancer
• 3. Written consent obtained before initiation of any study-related procedures
• 4. Definitive cancer treatment intent
• 5. Absence of current malignancies at other sites, except for adequately treated basal or squamous cell carcinoma of the skin. Cancer survivors who have undergone potentially curative therapy for a prior malignancy who have no evidence of that disease for 5 years and who are deemed at low risk for recurrence are eligible for the study.
• 6. Adequate liver (AST, ALT, Alk Phos, and Tbili \<2 fold upper limit) and kidney function (Cr \< 2.5 limit of normal and Cr clearance \>30)
• 7. ECOG 0-2
• 1. HIV infection, cellular immune deficiencies, hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital immunodeficiencies
• 2. Prior diagnosis of hepatitis B or C (unless anti-hepatitis C therapy has produced a sustained virologic response);
• 3. History of clinically significant autoimmune disease, Crohn's disease, ulcerative colitis, or inflammatory disease.
• 4. Serious concomitant disorder, including active systemic infection requiring treatment, as judged by the Investigator.
• 5. Known or suspected hypersensitivity to any component of the investigational product
• 6. Recurrent radiation to the treatment site
• 7. Prior major surgery within 4 weeks of enrollment from which the patient has not recovered
• 8. Other condition or prior therapy that, in the opinion of the Investigator, compromises the subject's welfare or may confound study results
• 9. Previous enrollment in this study
• 10. Pregnancy: a female subject defined as a WOCBP who has a positive urine pregnancy test (e.g. within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• 11. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
• 12. Patients must be capable of understanding and providing a written informed consent.
• 13. Patients with leukemias or lymphomas with T cell/histiocyte or NK cell rich component(s) and other variants not otherwise specified that contain high numbers of T or NK cells.
• 14. Evidence of clinically significant interstitial lung disease or active noninfectious pneumonitis during the course of chemoradiation that is unresolved to ≤ grade 1.
• 15. Patients with grade 4 toxicities during chemoradiation not resolved to grade ≤ 1 by the end of chemoradiation.
• 16. Prior exposure to IL-2 or IL-5.